Paula  M.  Fracasso
Degree(s): MD/PhD
Graduate School: Yale University
Primary Appointment: Professor, Medicine, Hematology and Oncology
Research Interests:
EGFR and cell cycle inhibitors in women's malignancies.
Email Address: pmf4v@virginia.edu
Research Description

Dr. Paula M. Fracasso, the Lawrence W. Penniston, M.D., Family Professor of Women’s Oncology Research, is the Deputy Director of the Cancer Center and the Section Chief of Medical Oncology. Dr. Fracasso's clinical research involves early drug development with an emphasis on women’s cancers. She is the Principal Investigator of a NCI R21 Quick Trials grant which explores the use of an investigational cell cycle inhibitor, UCN-01, in combination with irinotecan in women with in triple negative (estrogen and progesterone receptor and HER2 negative) advanced breast. She is also interested in EGFR inhibitors in combination with chemoradiation in locally advanced cervix cancer. She is the national chair of the Phase I Subcommittee and co-chair of the Developmental Therapeutics Committee in the National Cancer Institute’s Gynecologic Oncology Group (GOG) which is responsible for developing new therapies for women with gynecologic malignancies. She is a member of NCI's Operational Efficiency Working Group of the Clinical Trials Advisory Committee charged with implementing processes to reduce the time for activation of NCI-supported clinical trials.

Selected Publications
  • Wong, K.K., Fracasso, P.M., Bukowski, R.M., Lynch, T.J., Munster, P.N., Shapiro, G.I., Janne, P.A., Eder, J.P. Naughton, M.J., Ellis, M.J., Jones, S.F., Mekhail, T., Zacharchuk, C., Vermette, J., Abbas, R., Quinn, S., Powell, C., Burris, H.A. A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. Clin Cancer Res 2009; 15: 2552-2558.
  • Fracasso, P.M., Picus, J., Wildi, J.D., Goodner, S.A., Creekmore, A.N., Gao, F., Govindan, R., Ellis, M.J., Tan, B.R., Linette, G.P., Fu, C.J., Pentikis, H.S., Zumbrun, S.C., Egorin, M.J., Bellet, R.E. A Phase 1 and Pharmacokinetic Study of Weekly Docosahexaenoic Acid-Paclitaxel, Taxoprexin®, in Resistant Solid Tumor Malignancies. Cancer Chemother Pharmacol 2009; 63:451-458.
  • Eiblmaier, M., Meyer, L.A., Watson, M.A., Fracasso, P.M., Pike, L.J., Anderson, C.J., Correlating EGFR Expression with EGFR Receptor Binding Properties and Internalization of 64Cu-DOTA-C225 in Five Cervical Cancer Cell Lines, J Nucl Med. 2008; 49: 1472-1749.
  • Lhomme, C., Joly, F., Walker, J.L., Lissoni, A.A., Nicoletto, M.O., Manikhas, G.M., Baekelandt, M.O., Gordon, A.N., Fracasso, P.M., Mietlowski, W.L., Jones, G.J., Dugan, M.H. Phase III Study of Valspodar (PSC 833) Combined with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer. J Clin Oncol. 2008; 26: 2674-2682.
    • Intranet Profile
    [To add/update Intranet profile information, read these instructions.]
    Contact Information
      Office Address: PO Box 800716, 
      Office Phone: +1 434-243-6143
      Fax Phone: +1 434-982-4199

    (Find Out How to Update Your Faculty Profile)
    [empty string]